These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 23601084)

  • 1. Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects.
    Klumpers LE; Fridberg M; de Kam ML; Little PB; Jensen NO; Kleinloog HD; Elling CE; van Gerven JM
    Br J Clin Pharmacol; 2013 Dec; 76(6):846-57. PubMed ID: 23601084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.
    Klumpers LE; Roy C; Ferron G; Turpault S; Poitiers F; Pinquier JL; van Hasselt JG; Zuurman L; Erwich FA; van Gerven JM
    Br J Clin Pharmacol; 2013 Jul; 76(1):65-77. PubMed ID: 23278647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: a PET study.
    Takano A; Gulyás B; Varnäs K; Little PB; Noerregaard PK; Jensen NO; Elling CE; Halldin C
    Synapse; 2014 Mar; 68(3):89-97. PubMed ID: 24293119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic/pharmaco-dynamic modelling and simulation of the effects of different cannabinoid receptor type 1 antagonists on Δ(9)-tetrahydrocannabinol challenge tests.
    Guan Z; Klumpers LE; Oyetayo OO; Heuberger J; van Gerven JM; Stevens J
    Br J Clin Pharmacol; 2016 Apr; 81(4):713-23. PubMed ID: 26617196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antagonist-elicited cannabis withdrawal in humans.
    Gorelick DA; Goodwin RS; Schwilke E; Schwope DM; Darwin WD; Kelly DL; McMahon RP; Liu F; Ortemann-Renon C; Bonnet D; Huestis MA
    J Clin Psychopharmacol; 2011 Oct; 31(5):603-12. PubMed ID: 21869692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Cannabinoid CB1 Antagonist TM38837 With Limited Penetrance to the Brain Shows Reduced Fear-Promoting Effects in Mice.
    Micale V; Drago F; Noerregaard PK; Elling CE; Wotjak CT
    Front Pharmacol; 2019; 10():207. PubMed ID: 30949045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers.
    Gorelick DA; Heishman SJ; Preston KL; Nelson RA; Moolchan ET; Huestis MA
    Am Heart J; 2006 Mar; 151(3):754.e1-754.e5. PubMed ID: 16504646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Cannabinoid Agonists and Antagonists on Sleep and Breathing in Sprague-Dawley Rats.
    Calik MW; Carley DW
    Sleep; 2017 Sep; 40(9):. PubMed ID: 28934522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716.
    Huestis MA; Gorelick DA; Heishman SJ; Preston KL; Nelson RA; Moolchan ET; Frank RA
    Arch Gen Psychiatry; 2001 Apr; 58(4):322-8. PubMed ID: 11296091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys.
    Schindler CW; Redhi GH; Vemuri K; Makriyannis A; Le Foll B; Bergman J; Goldberg SR; Justinova Z
    Neuropsychopharmacology; 2016 Aug; 41(9):2283-93. PubMed ID: 26888056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rimonabant effects on anxiety induced by simulated public speaking in healthy humans: a preliminary report.
    Bergamaschi MM; Queiroz RH; Chagas MH; Linares IM; Arrais KC; de Oliveira DC; Queiroz ME; Nardi AE; Huestis MA; Hallak JE; Zuardi AW; Moreira FA; Crippa JA
    Hum Psychopharmacol; 2014 Jan; 29(1):94-9. PubMed ID: 24424711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists.
    Kangas BD; Delatte MS; Vemuri VK; Thakur GA; Nikas SP; Subramanian KV; Shukla VG; Makriyannis A; Bergman J
    J Pharmacol Exp Ther; 2013 Mar; 344(3):561-7. PubMed ID: 23287700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy in diet-induced obese mice of the hepatotropic, peripheral cannabinoid 1 receptor inverse agonist TM38837.
    Cooper ME; Nørregaard PK; Högberg T; Andersson G; Receveur JM; Linget JM; Elling CE
    Br J Pharmacol; 2024 Oct; 181(20):3926-3943. PubMed ID: 38886096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans.
    Beaumont H; Jensen J; Carlsson A; Ruth M; Lehmann A; Boeckxstaens G
    Br J Pharmacol; 2009 Jan; 156(1):153-62. PubMed ID: 19068079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CB1 - cannabinoid receptor antagonist effects on cortisol in cannabis-dependent men.
    Goodwin RS; Baumann MH; Gorelick DA; Schwilke E; Schwope DM; Darwin WD; Kelly DL; Schroeder JR; Ortemann-Renon C; Bonnet D; Huestis MA
    Am J Drug Alcohol Abuse; 2012 Jan; 38(1):114-9. PubMed ID: 21797816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats.
    Järbe TU; LeMay BJ; Vemuri VK; Vadivel SK; Zvonok A; Makriyannis A
    Psychopharmacology (Berl); 2011 Aug; 216(3):355-65. PubMed ID: 21369753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.
    Seely KA; Brents LK; Franks LN; Rajasekaran M; Zimmerman SM; Fantegrossi WE; Prather PL
    Neuropharmacology; 2012 Oct; 63(5):905-15. PubMed ID: 22771770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissociable effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in the novelty-induced hypophagia test in mice.
    Gamble-George JC; Conger JR; Hartley ND; Gupta P; Sumislawski JJ; Patel S
    Psychopharmacology (Berl); 2013 Aug; 228(3):401-9. PubMed ID: 23483200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel 3-substituted rimonabant analogues lack Δ(9) -tetrahydrocannabinol-like abuse-related behavioural effects in mice.
    Walentiny D; Vann R; Mahadevan A; Kottani R; Gujjar R; Wiley J
    Br J Pharmacol; 2013 May; 169(1):10-20. PubMed ID: 23297801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569.
    Gamage TF; Ignatowska-Jankowska BM; Wiley JL; Abdelrahman M; Trembleau L; Greig IR; Thakur GA; Tichkule R; Poklis J; Ross RA; Pertwee RG; Lichtman AH
    Behav Pharmacol; 2014 Apr; 25(2):182-5. PubMed ID: 24603340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.